Opsumit and Tresiba drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Opsumit (macitentan) and Tresiba (insulin degludec). Common drug interactions include pulmonary hypertension among females and sepsis among males.

The phase IV clinical study analyzes what interactions people have when they take Opsumit and Tresiba. It is created by eHealthMe based on reports of 35 people who take the same drugs from the FDA, and is updated regularly.

What is Opsumit?

Opsumit has active ingredients of macitentan. eHealthMe is studying from 67,926 Opsumit users. Check the latest studies of Opsumit.

What is Tresiba?

Tresiba has active ingredients of insulin degludec. It is often used in type 1 diabetes. eHealthMe is studying from 20,677 Tresiba users. Check the latest studies of Tresiba.



On Jul, 10, 2026

35 people who take Opsumit and Tresiba together, and have interactions are studied.

Opsumit and Tresiba drug interactions.

What are the common drug interactions of Opsumit and Tresiba, by gender? *:

female:

  1. Pulmonary hypertension (increase in blood pressure in the lung artery)
  2. Rash
  3. Right ventricular failure (right half of the heart fails to work)
  4. Surgery
  5. Urticaria (rash of round, red welts on the skin that itch intensely)
  6. Weight decreased
  7. Nausea (feeling of having an urge to vomit)
  8. Headache (pain in head)
  9. Chest pain
  10. Cardiac failure

male:

  1. Sepsis (a severe blood infection that can lead to organ failure and death)
  2. Cardiac discomfort
  3. Arrhythmia (irregular heartbeat)
  4. Ascites (accumulation of fluid in the abdominal cavity)
  5. Diabetic foot
  6. Diabetic foot infection
  7. Oedema (fluid collection in tissue)
  8. Osteomyelitis chronic (long lasting infection of bone marrow)
  9. Fall
  10. Pulmonary arterial hypertension (high blood pressure in the arteries of lungs)

What are the common drug interactions of Opsumit and Tresiba, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Nausea (feeling of having an urge to vomit)
  2. Headache (pain in head)
  3. Chest pain
  4. Palpitations (feelings or sensations that your heart is pounding or racing)
  5. Cardiac failure
  6. Dizziness
  7. Hypoglycaemia (deficiency of glucose in the bloodstream)
  8. Malaise (a feeling of general discomfort or uneasiness)
  9. Extrasystoles
  10. Atrial tachycardia (rhythm disturbance that arises in the atria)

40-49:

n/a

50-59:

  1. Arrhythmia (irregular heartbeat)
  2. Ascites (accumulation of fluid in the abdominal cavity)
  3. Oedema (fluid collection in tissue)
  4. Fall
  5. Pulmonary arterial hypertension (high blood pressure in the arteries of lungs)
  6. Blood glucose decreased
  7. Chills (felling of cold)
  8. Feeling cold
  9. Malaise (a feeling of general discomfort or uneasiness)
  10. Blood pressure decreased

60+:

  1. Dyspnoea (difficult or laboured respiration)
  2. Fluid retention (an abnormal accumulation of fluid in the blood)
  3. Post procedural infection
  4. Pulmonary oedema (fluid accumulation in the lungs)
  5. Sepsis (a severe blood infection that can lead to organ failure and death)
  6. Tremor (trembling or shaking movements in one or more parts of your body)
  7. Cough
  8. Cardiac failure
  9. Diabetic foot
  10. Diabetic foot infection

What are the existing conditions these people have? *

  1. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 31 people, 88.57%
  2. Hyperuricaemia (level of uric acid in the blood that is abnormally high): 9 people, 25.71%
  3. Diabetes: 7 people, 20.00%
  4. Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 6 people, 17.14%
  5. Hypokalemia (low potassium): 6 people, 17.14%
  6. Gastritis - Chronic (long lasting inflammation of stomach): 6 people, 17.14%
  7. Bronchitis Chronic (inflammation of the mucous membrane in the bronchial tubes- chronic): 6 people, 17.14%
  8. Type 2 Diabetes: 3 people, 8.57%
  9. Mesenteric Vein Thrombosis (blood clot in mesenteric vein): 3 people, 8.57%
  10. Hepatitis C: 3 people, 8.57%

* Approximation only. Some reports may have incomplete information.

Do you take Opsumit and Tresiba?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Opsumit and Tresiba:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Opsumit:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Tresiba:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Opsumit and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Tresiba and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on macitentan and insulin degludec (the active ingredients of Opsumit and Tresiba, respectively), and Opsumit and Tresiba (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: